Recombinant COVID-19 Trivalent (XBB.1.5+BA.5+Delta) Protein Vaccine (Sf9 Cell)(Chengdu WestVac)

重组三价新冠病毒（XBB.1.5+BA.5+Delta变异株）三聚体蛋白疫苗（Sf9细胞）(成都威斯克)

Report date: 2025/07/08 13:31:52

Base Information

Drug NameRecombinant COVID-19 Trivalent (XBB.1.5+BA.5+Delta) Protein Vaccine (Sf9 Cell)(Chengdu WestVac)
Drug Alias Name重组三价新冠病毒（XBB+BA.5+Delta变异株）三聚体蛋白疫苗（Sf9细胞）(成都威斯克)Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)(Chengdu WestVac)威克欣®3价XBB疫苗WSK-V102C
ClassificationVaccines > Development/production technology > Genetically engineered subunit vaccineVaccines > Vaccine type > Multivalent vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulantsCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaCoronavirus Disease 2019 (COVID-19)
Original Approved Country/TerritoryMainland China
Original Approved Date2023/06/08
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesChengdu WestVac Biopharma Co LtdWest China Hospital Of Sichuan University
China Registration ClassN/A

Develop Information

Active CompaniesChengdu WestVac Biopharma Co LtdWest China Hospital Of Sichuan University
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A